Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Trifecta-Lung cfDNA-MMDx Study
NCT05837663 · View on ClinicalTrials.gov ↗
Study Summary
Demonstrate the relationship between dd-cfDNA levels and HLA antibodies in blood transplant recipient and Demonstrate the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from lung transplants.
Conditions Studied
Study Locations (18)
Texas
- BAYLOR SCOTT & WHITE RESEARCH INSTITUTE , 3409 Worth Street — Dallas
- UT Southwestern Medical Center, 5939 Harry Hines Blvd. — Dallas
- Houston Methodist Lung Transplant Center, 6550 Fannin St., SM1001 — Houston
- UT Health San Antonio 7703 Floyd Curl Drive, MSC: 7858 — San Antonio
Other
- The Alfred Hospital, Monash University — Melbourne
- Department of Thoracic Surgery, Medical University of Vienna — Vienna
- Motol University Hospital, V Uvalu 84 — Prague
- Charles University/Hospital Motol — Prague
Florida
- Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, College of Medicine — Gainesville
- USF Health, Morsani College of Medicine, 12901 Bruce B. Downs Blvd. MDC40 — Tampa
Alberta
- Department of Medicine, University of Alberta — Edmonton
- Alberta Transplant Applied Genomics Centre, University of Alberta — Edmonton
Arizona
- St. Joseph's Hospital and Medical Center 350 West Thomas Road, Floor 8HLT — Phoenix
Indiana
- Indiana University Methodist Hospital 1812 N. Capitol Ave Suite W131L — Indianapolis
Maryland
- Johns Hopkins Interventional Pulmonology, Sheikh Zayed Tower, Room 7125L, 1800 Orleans Street — Baltimore
New York
- Division of Pulmonary, Allergy & Critical Care Medicine Columbia University Irving Medical Center — New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2027-12 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05837663
The ClinicalTrials.gov registry entry for NCT05837663 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alberta, which has 135 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Lung Transplantation appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05837663 reports 18 study locations spanning 10 distinct geographic areas — top geographies include Texas, Other, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05837663 about?
NCT05837663 is a clinical study titled "Trifecta-Lung cfDNA-MMDx Study". Demonstrate the relationship between dd-cfDNA levels and HLA antibodies in blood transplant recipient and Demonstrate the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from lung transplants.
What is the current status of trial NCT05837663?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2023-11-01. Estimated completion is 2027-12.
What conditions does trial NCT05837663 study?
This clinical trial studies the following conditions: Lung Transplantation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT05837663?
This trial is sponsored by University of Alberta, which has 135 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05837663 being conducted?
This trial has 18 study locations across Arizona, Florida, Indiana, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.